Mesoblast Ltd (ASX:MSB, NASDAQ:MESO) shares traded lower on Monday, slipping nearly 4% by 3 pm AEDT despite what, on the surface, looked like constructive regulatory feedback from the US Food and Drug Administration acknowledging the potential efficacy of the company’s chronic back pain treatment.
The stock’s reaction offered a reminder that positive regulatory language does not always translate into immediate market gains — particularly when the news confirms potential rather than delivering a clear approval pathway. The decline came against a broader market that was already under pressure, with the ASX 200 down 0.48% and the healthcare sector off around 0.44%.
What the FDA said
The catalyst was feedback from the FDA following a Type B meeting on Mesoblast’s proposed Biologics License Application (BLA) for rexlemestrocel-L, its allogeneic cell therapy for chronic discogenic low back pain.
Importantly, the regulator acknowledged that results from Mesoblast’s first Phase 3 trial appeared to favour the active treatment over placebo in terms of pain intensity reduction. The FDA also confirmed that a clinically meaningful reduction in pain at 12 months could support product efficacy — a key requirement for approval.
Perhaps most notably, the agency said robust opioid-reduction data from at least one adequate and well-controlled trial could be included in the product’s labelling under the Clinical Studies section. That matters because chronic low back pain is a major contributor to opioid use in the US, and rexlemestrocel-L has already been granted Regenerative Medicine Advanced Therapy (RMAT) designation.
On paper, it was a supportive read-through. The FDA did not reject the approach, dispute the endpoint, or require a redesign of the program.
Why the stock still fell
So why the sell-off?
First, the announcement didn’t fundamentally change Mesoblast’s near-term timeline. The company is still recruiting its second confirmatory Phase 3 trial, which is only just past the halfway mark and expected to complete enrolment over the next few months. Until those data are locked in, a BLA filing — let alone approval — remains some distance away.
Second, the FDA language, while constructive, was careful. Acknowledging that data “appear to favour” the active arm is not the same as endorsing a filing today, and markets are increasingly sensitive to nuance in regulatory phrasing. For investors hoping for a clearer green light, the update may have felt incremental rather than decisive.
There’s also the broader context of recent share price performance. Mesoblast is down more than 8% over the past week and more than 12% over the past month. In that setting, any strength tends to be met with selling from investors looking to reduce exposure or lock in short-term gains.
The longer-term significance
Stepping back, the FDA’s comments do reinforce the strategic rationale behind rexlemestrocel-L.
The therapy targets inflammatory degenerative disc disease — a condition affecting millions of Americans and responsible for a substantial proportion of prescription opioid use. In Mesoblast’s first Phase 3 trial, patients treated with rexlemestrocel-L were significantly more likely to cease opioid use altogether over a multi-year follow-up period.
That combination — durable pain reduction and opioid sparing — aligns neatly with recent FDA guidance encouraging development of non-opioid treatments for chronic pain. It also explains why Mesoblast is leaning into the potential labelling opportunity around opioid reduction, even if that element alone won’t carry an approval.
The company’s challenge now is execution. Completing enrolment, maintaining statistical consistency across trials and navigating the BLA process will all be critical. Until then, investor patience will be tested, as will tolerance for volatility.
For Monday at least, the market chose caution over optimism, reminding biotech watchers that regulatory encouragement is valuable, but proof — and approvals — still matter most.